What

Femitas Lead Product - Cicletanine

Challenge

Activates eNOS, an enzyme core to endothelial function

Endothelial dysfunction

  • Decreases levels of adrenaline and noradrenaline

  • Specific mechanistic data are available under confidentiality

Sympathetic overdrive

  • Inhibits activity of marinobufagenin, an endogenous steroid involved in salt-sensitive hypertension

  • Modulates a combination of kidney ion channels and ion exchangers

  • Details are available under confidentiality

Salt-sensitive hypertension

Cicletanine has favorable data in patients >60 corroborating genre-differential efficacy in women

Note: This study washed out other HTN drugs prior to CIC initiation. The planned CIC study would dose CIC vs. placebo on top of existing HTN drugs, washing out thiazides only (≥7 days before study initiation)

  • 60 patients, taking CIC 150 mg or placebo 1x/day

    • q15-day placebo run-in, followed by 24 weeks on placebo or CIC

    • qNo other hypertension medications allowed during the study

  • Two placebo patients withdrew during the trial; their last recorded BP values were used as 24-week data

  • Between-gender differences:

    • qWomen had greater DBP reduction than men (P= 0.001)

    • qWomen trended better than men for reduction of SBP and pulse pressure